Michael Brody, MD
Gastroenterology · Cary, NCNPI 1407948110
Payments from drug & device makers
Across 105 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$445
- AbbVie$362
- Pfizer$311
- Bristol Myers Squibb$197
- Sanofi$151
- Aimmune Therapeutics, Inc.$67
- plus $421 from 15 others
What the payments were for
- Food & beverage$1,93799%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $445 |
| AbbVie | 22 | $362 |
| Pfizer | 19 | $311 |
| Bristol Myers Squibb | 10 | $197 |
| Sanofi | 5 | $151 |
| Aimmune Therapeutics, Inc. | 3 | $67 |
| Intra-sana Laboratories | 2 | $64 |
| Intercept Pharmaceuticals, Inc. | 3 | $59 |
| UCB, Inc. | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Boston Scientific | 1 | $33 |
| Ardelyx, Inc. | 1 | $24 |
| Johnson & Johnson | 2 | $23 |
| Celltrion USA Inc. | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Merck | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
How this compares
$1,955 in reported general payments places this provider in the 45th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 307 | $22,106 |
| VoqueznaVonoprazan Fumarate | 14 | $11,221 |
| Mesalamine ErMesalamine | 17 | $5,963 |
| Mesalamine | 11 | $4,895 |
| Sucralfate | 33 | $3,455 |
| Famotidine | 213 | $3,266 |
| Omeprazole | 241 | $3,146 |
| Pantoprazole Sodium | 254 | $2,870 |
| Colestipol Hcl | 27 | $1,786 |
| Esomeprazole Magnesium | 49 | $1,667 |
| CholestyramineCholestyramine (With Sugar) | 15 | $818 |
| Budesonide DrBudesonide | 15 | $796 |
| Rabeprazole Sodium | 26 | $651 |
| Sulfasalazine | 16 | $480 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $235 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Cary
- Christopher McGowanCary$1M
- Nidhi MalhotraCary$177K
- Subhash GumberCary$167K
- Evan DellonChapel Hill$11.2M
- Andrew MuirDurham$6.6M
- Manal AbdelmalekDurham$5.6M
- Robert ReindollarSalisbury$2.5M
- John PoulosFayetteville$2.1M
- Hans HerfarthChapel Hill$2M
- Herbert BonkovskyWinston Salem$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.